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Abstract
Research in autophagy continues to accelerate,1 and as a result many new scientists are entering the
field. Accordingly, it is important to establish a standard set of criteria for monitoring
macroautophagy in different organisms. Recent reviews have described the range of assays that have
been used for this purpose.2,3 There are many useful and convenient methods that can be used to
monitor macroautophagy in yeast, but relatively few in other model systems, and there is much
confusion regarding acceptable methods to measure macroautophagy in higher eukaryotes. A key
point that needs to be emphasized is that there is a difference between measurements that monitor
the numbers of autophagosomes versus those that measure flux through the autophagy pathway; thus,
a block in macroautophagy that results in autophagosome accumulation needs to be differentiated
from fully functional autophagy that includes delivery to, and degradation within, lysosomes (in most
higher eukaryotes) or the vacuole (in plants and fungi). Here, we present a set of guidelines for the
selection and interpretation of the methods that can be used by investigators who are attempting to
examine macroautophagy and related processes, as well as by reviewers who need to provide realistic
and reasonable critiques of papers that investigate these processes. This set of guidelines is not meant
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to be a formulaic set of rules, because the appropriate assays depend in part on the question being
asked and the system being used. In addition, we emphasize that no individual assay is guaranteed
to be the most appropriate one in every situation, and we strongly recommend the use of multiple
assays to verify an autophagic response.
Keywords
autolysosome; autophagosome; flux; lysosome; phagophore; stress; vacuole
At the first Keystone Symposium on Autophagy in Health and Disease, one of the researchers
in the audience, after listening to several comments detailing inadequacies in documenting
autophagy, asked the question “What are the essential criteria for demonstrating autophagy?”
This is a reasonable question, particularly considering that each of us may have his/her own
opinion regarding the answer. Unfortunately, this presents something of a “moving target” for
researchers who may think they have met those criteria, only to find out that the reviewer of
their paper has different ideas. Conversely, as a reviewer, it is tiresome to raise the same
objections repeatedly, wondering why researchers have not fulfilled some of the basic
requirements for establishing the occurrence of an autophagic process. In addition, drugs that
potentially modulate autophagy are increasingly being used in clinical trials, and screens are
being carried out for new drugs that can modulate autophagy for therapeutic purposes. Clearly
it is important to determine whether these drugs are truly affecting autophagy based on a set
of accepted criteria. Accordingly, we describe here a basic set of contemporary guidelines that
can be used by researchers to plan and interpret their experiments, by clinicians to decide which
avenue of treatment is appropriate, and by both authors and reviewers to justify or criticize an
experimental approach.
Several fundamental points must be kept in mind as we establish guidelines for the selection
of appropriate methods to monitor autophagy. Importantly, there are no absolute criteria for
determining the autophagic status that apply to every situation. This is because some assays
are inappropriate, problematic or may not work at all in particular cells, tissues or organisms.
2 In addition, these guidelines may evolve as new methodologies are developed and current
assays of the process are superseded. Nonetheless, it is useful to establish guidelines for
acceptable assays that can reliably monitor autophagy in many experimental systems. It is
important to note that in this set of guidelines the term “autophagy” generally refers to
macroautophagy; other autophagy-related processes are specifically designated when
appropriate.
An important point is that autophagy is a dynamic, multi-step process that can be modulated
at several steps, both positively and negatively. In this respect, the autophagic pathway is not
different from other cellular pathways. An accumulation of autophagosomes (be they measured
by electron microscopy (EM) image analysis, as fluorescent GFP-LC3 dots, or as LC3
lipidation on a western blot), could, for example, reflect either increased autophagosome
formation due to increases in autophagic activity, or to reduced turnover of autophagosomes
(Fig. 1). The latter can occur by inhibiting their maturation to amphisomes or autolysosomes,
which happens if there are defects in fusion with endosomes or lysosomes, respectively, or
following inefficient degradation of the cargo once fusion has occurred.4 For the purposes of
this review, the autophagic compartments are referred to as the sequestering
(preautophagosomal) phagophore,5 the autophagosome,6 the amphisome (generated by fusion
of autophagosomes with endosomes, also referred to as an acidic late autophagosome7)8 and
the autolysosome (generated by fusion of autophagosomes or amphisomes with a lysosome,
also referred to as an autophagolysosome).6 We note that the use of the term “phagophore” in
this review has no implied meaning in regard to the origin of the autophagosomal membrane.
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The word “phagophore” was originally coined to indicate that the initial sequestering structure
was morphologically distinct from other organelles.5 Other studies, however, suggest specific
origins for the autophagosome sequestering membrane, most notably the endoplasmic
reticulum.9 Indeed, recent work suggests that the endoplasmic reticulum, and more generally
membrane flow through the secretory pathway, is required for autophagosome formation.10,
11 A complete understanding of the membrane source(s) for autophagy awaits further study
and, accordingly, “phagophore” in the context of this review refers only to a particular structure.
Studies related to autophagic cell death or, more properly (because it is seldom verified that
autophagy is the mechanism underlying such programmed cell death), autophagy-associated
cell death, represent another important situation where it becomes necessary to distinguish
whether the phenotypic defects arise due to the inhibition versus induction of autophagy. In
some cases, this type of death is due to reduced autophagic flux, due to inhibition of the fusion
of autophagosomes with lysosomes or to loss of the degradative functions of lysosomes.12
Therefore, the use of autophagy markers such as LC3-II needs to be complemented by
knowledge of overall autophagic flux to permit a correct interpretation of the results. In this
case, one needs to measure the rate of general autophagic protein breakdown, or to arrest the
autophagic flux at a given point to record the time-dependent accumulation of an organelle, an
organelle marker, a cargo marker or the entire cargo at the point of blockage. Along the same
lines, one can follow the time-dependent decrease of appropriate markers. In theory, this can
be achieved by blocking autophagic sequestration at specific steps of the pathway (e.g.,
blocking further induction or nucleation of a new phagophore) and by measuring the decrease
of markers behind the block point. The key issue is to differentiate between the formation
versus accumulation of autophagosomes by measuring “steady state” levels and the rates of
autophagic degradation of cellular components. Both processes have been used to estimate
“autophagy” but unless the experiments can relate changes in autophagosome numbers to a
direct or indirect measurement for autophagic flux (e.g., clearance of a substrate as a direct
measurement, or changes in LC3-II as an indirect measurement), they may be difficult to
interpret. A general caution regarding the use of the term “steady state” is warranted at this
point. It should not be assumed that an autophagic system is at steady state as this implies that
the level of autophagosomes does not change with time and the flux through the system is
constant. Rather, in this review we use the term steady state to refer to measurements that are
static in nature.
Autophagic flux refers to the complete process of autophagy including the delivery of cargo
to lysosomes (via fusion of the latter with autophagosomes or amphisomes) and its subsequent
breakdown and recycling. Thus, increases in the level of phosphatidylethanolamine-modified
LC3 (LC3-II), or even the appearance of autophagosomes are not measures of autophagic flux
per se, but can reflect the induction of autophagy and/or inhibition of autophagosome or
amphisome clearance. Furthermore, the degradative capacity of a cell, which likely varies with
cell type, age, transformation and/or disease, may determine the outcome of autophagy
induction.13 Finally, it is important to note that while formation of LC3-II correlates with the
induction of autophagy, we do not know, at present, the actual mechanistic relationship between
LC3-II formation and the rest of the autophagic process. Accordingly, it is essential to
distinguish between autophagosome or LC3-II accumulation, and autophagic flux.
As a final note, we also recommend that authors refrain from the use of the expression “percent
autophagy” when describing experimental results, as in “The cells displayed a 25% increase
in autophagy.” In contrast, it is appropriate to indicate that a certain percentage of cells display
punctate GFP-LC3, or that there is a particular increase or decrease in the rate of degradation
of long-lived proteins, as these are the actual measurements being quantified.
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Collectively, we propose the following guidelines for measuring these various aspects of
autophagy in higher eukaryotes:
A. Monitoring Phagophore and Autophagosome Formation by Steady State
Methods
The key reason for separating these guidelines into sections on steady state versus flux
measurements is that the former rely on methods that indicate the induction of autophagy, but
do not allow a determination of whether the process goes to completion. This is an important
point because incomplete autophagy, which would lead to the accumulation of
autophagosomes contributes to physiological dysfunction. In contrast, complete autophagy
will generally exert a cytoprotective effect.
1. Electron microscopy
Autophagy was first detected by electron microscopy. The focal degradation of cytoplasmic
areas sequestered by the phagophore (a specialized type of smooth, ribosome-free double
membrane), which matures into the prelysosomal autophagosome is the hallmark of autophagy.
Therefore, the use of electron microscopy is a valid and important method both for the
qualitative and quantitative analysis of changes in various autophagic structures that
sequentially form, the phagophore, autophagosome, amphisome and autolysosome (Fig. 1).
The maturation from the phagophore through the autolysosome is a dynamic and continuous
process,14 and thus the classification of compartments into discrete morphological subsets can
be problematic. Fortunately, for many biological and pathological situations, examination of
both early and late autophagic structures yields valuable data regarding the overall autophagy/
lysosomal status in the cells.13
Cautionary notes—Although EM is one of the most widely used methodologies to monitor
autophagy, it is also one of the most problematic and prone to misinterpretation. Due to the
large potential for sampling artifact, careful selection of appropriate nonbiased methods of
quantification and morphometric/stereological analyses are essential.15 For example, it is
better to count autophagosome profiles than to just score for the presence or absence of
autophagosomes in the section of a cell, but the preferred method is to quantify autophagosome
volume as the percent of cytoplasmic volume using volumetric morphometry/stereology.16
During quantification it is important to make sure that every cell profile in the thin section has
equal probability to be included in the counting.
The reliable identification of the autophagosome is a prerequisite for a valid analysis. An
additional complication, however, is that maturation of mammalian autophagosomes involves
a transition to single-membrane structures (i.e., amphisomes and autolysosomes).17 Thus,
double membranes do not necessarily represent evidence for ultrastructural identification of
autophagy-related structures, and it is important to employ expert analysis to avoid
misinterpretation of micrographs. Even among experts, there is some disagreement as to the
characteristics of an authentic autophagosome.18 For example, starvation-induced
autophagosomes should contain cytoplasm (i.e., cytosol and possibly organelles), but
autophagosome-related structures involved in specific types of autophagy, such as selective
peroxisome or mitochondria degradation (pexophagy or mitophagy, respectively) or targeted
degradation of pathogenic microbes (xenophagy), may be relatively devoid of cytoplasm.
Furthermore, some pathogenic microbes express membrane-disrupting factors during infection
(e.g., phospholipases) that disrupt the normal double-membrane architecture of
autophagosomes.19 It is not even clear if the sequestering compartments used for specific
organelle degradation or xenophagy should be termed autophagosomes or if alternate terms
such as pexophagosome20 and xenophagosome should be used, even though the membrane
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and mechanisms involved in their formation may be identical to those for starvation-induced
autophagosomes. It is also difficult to determine whether material present within a phagosomal
structure derives from self-eating, or from a heterophagic process; when appropriate, specific
analyses can be performed to assess the source of the engulfed material. Regardless, it is
necessary to prove that the sequestered content becomes completely degraded within the
membrane-bordered space. This is accomplished by demonstrating that sequential
disintegration of well-recognizable sequestered structures (e.g., mitochondria or rough
endoplasmic reticulum cisternae) proceeds to completion. The fact that the entire disintegration
process remains focal is evidence for being completely bordered by a membrane in three
dimensions. Demonstration of the presence of lysosomal enzymes in post-fusion autophagic
compartments by traditional immunocytochemistry is also feasible. Finally, due to the cisternal
structure of the endoplasmic reticulum, double membrane-like structures surrounding
mitochondria or other organelles are often observed after sectioning, which actually correspond
to cisternae of the ER coming into and out of the section plane. The presence of ribosomes
associated with these membranes helps distinguish them from the ribosome-free double-
membrane of the autophagosome.
In case of potential uncertainties, it is desirable to use immuno-EM with gold-labeling,21,22
using antibodies to cargo proteins (of cytosolic origin; in this case the cargo should not be an
abundant cytosolic protein or the background will be too high, but organelle markers work
well) and to LC3 to verify the autophagic nature of the compartment. The success of this
methodology, however, depends on the quality of the antibodies and also on the EM preparation
and fixation procedures required. With immuno-EM, authors should provide controls showing
that labeling is specific, by demonstrating that the signal is clearly above background. In
addition, we recommend that statistical information be provided due to the necessity of showing
only a selective number of sections. Again, we note that for quantitative data it is preferable
to use proper volumetric analysis rather than just counting numbers of sectioned objects. It
must be kept in mind, however, that even volumetric morphometry/stereology only shows
steady state levels, and by itself is not informative regarding autophagic flux. On the other
hand, quantitative analyses indicate that autophagosome volume in many cases does correlate
with the rates of protein degradation.23–25
One additional caveat with EM, and to some extent with confocal fluorescence microscopy, is
that the analysis of single sections of a cell can be misleading and may make the identification
of autophagic structures difficult. One potential compromise is to perform whole cell
quantification of autophagosomes using fluorescence methods, with qualitative verification by
EM,26 to show that the changes in fluorescent puncta reflect increases in autophagic structures.
Confocal microscopy and fluorescence microscopy with deconvolution software (or with much
more work, EM) can be used to generate multiple/serial sections of the same cell to reduce this
concern, but this is generally unnecessary because analyzing single sections of multiple cells
is more practical and provides more information. An additional methodology that is worth
noting is correlative light and electron microscopy, CLEM, which is helpful in confirming that
fluorescent structures are autophagosomes.27 Finally, although an indirect measurement, a
comparison of the ratio of autophagosomes to autolysosomes by EM can support alterations
in autophagy identified by other procedures.28 In this case it is important to always compare
samples to the control of the same cell type, as the ratio of autophagosome/autolysosome varies
in a cell context-dependent fashion, depending on their clearance activity. It may also be
necessary to distinguish autolysosomes from telolysosomes/late secondary lysosomes (the
former are actively engaged in degradation, whereas the latter have reached an end point in the
breakdown of lumenal contents; see part B, section 10) because lysosome numbers generally
increase when autophagy is induced.
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2. Atg8/LC3 western blotting and ubiquitin-like protein conjugation systems
The Atg8/LC3 protein is a ubiquitin-like protein that can be conjugated to
phosphatidylethanolamine (PE). In yeast, the conjugated form is referred to as Atg8—PE. The
mammalian homologues of Atg8 constitute a family of proteins, with microtubule-associated
protein 1 light chain 3 (LC3) being the most relevant for this discussion (this protein is referred
to as “Atg8” in other systems, but for simplicity we primarily refer to it here as LC3 to
distinguish it from the yeast protein). LC3 is initially synthesized in an unprocessed form,
proLC3, which is converted into a proteolytically processed form lacking amino acids from
the C terminus, LC3-I, and is finally modified into the PE-conjugated form, LC3-II (Fig. 2).
Atg8—PE/LC3-II is the only protein marker that is reliably associated with completed
autophagosomes, but is also localized to phagophores. In yeast, Atg8 amounts increase at least
ten-fold when autophagy is induced.29 In mammalian cells, however, the total levels of LC3
do not necessarily change, as there may be increases in the conversion of LC3-I to LC3-II, or
a decrease in LC3-II relative to LC3-I if degradation of LC3-II via lysosomal turnover is
particularly rapid. Furthermore, even if the total amount of LC3 does increase, the magnitude
of the response is generally less than that documented in yeast. Western blotting can easily be
used to monitor changes in LC3 amounts (Fig. 2). Note, however, that LC3-II western blotting
has not been used successfully in Drosophila melanogaster (Baehrecke E, Neufeld T,
unpublished results).
Cautionary notes—There are two important caveats when using LC3-II to follow
autophagy. First, changes in LC3-II amounts are tissue- and cell context-dependent.30,31
Indeed, in some cases, autophagosome accumulation detected by electron microscopy does not
correlate well with the amount of LC3-II (Tallóczy Z, de Vries RLA, and Sulzer D, and
Eskelinen E-L, unpublished results). Conversely, a normal level of LC3-II is not sufficient
evidence for autophagy. For example, homozygous deletion of beclin 1 does not prevent the
formation of LC3-II in embryonic stem cells even though autophagy is defective, whereas
deletion of atg5 does result in the complete absence of LC3-II (see Fig. 2B and suppl. data in
ref. 32). Thus, it is important to remember that not all of the autophagy-related proteins are
required for Atg8/LC3 processing, including lipidation. Vagaries in the detection and amounts
of LC3-I versus LC3-II present technical problems. For example, LC3-I is very abundant in
brain tissue, and the intensity of the LC3-I band may obscure detection of LC3-II, unless the
polyacrylamide crosslinking density is optimized. Conversely, certain cell lines have much
less visible LC3-I compared to LC3-II. In addition, tissues may have asynchronous and
heterogeneous cell populations, and this may present challenges when analyzing LC3 by
western blotting.
Second, caution must be exercised in general when evaluating LC3 by western blotting, and
appropriate standardization controls are necessary. For example, LC3-I may be less sensitive
to detection by certain anti-LC3 antibodies, and LC3-I is more labile than LC3-II. LC3-I is
also more sensitive to freezing-thawing and to degradation in SDS sample buffer, so fresh
samples should be boiled and assessed as soon as possible and should not be subjected to
repeated freeze-thaw cycles. Caveats regarding detection of LC3 by western blotting have been
covered in a recent review,33 but one important suggestion noted here is that one should
measure levels of LC3-II relative to actin and not to that of LC3-I. In addition, Triton X-100
may not efficiently solubilize LC3-II.34 Instead, heating in the presence of 1% SDS is needed
to ensure complete solubilization, which is essential for correct interpretation of results from
western blotting. Also, the utility of measuring LC3-I depends on the cells being analyzed. For
example, in contrast to cells from peripheral tissues, LC3-I is abundant and stable in central
nervous system tissue, and here both the ratio of LC3-II to LC3-I and the amount of LC3-II
can be used to monitor autophagosome formation.35 Finally, LC3 is expressed as three
isoforms in mammalian cells, LC3A, LC3B and LC3C,36 which exhibit different tissue
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distributions, and it may be necessary to use different antisera or antibodies that distinguish
among these isoforms. A point of caution along these lines is that the increase in LC3B-II
levels, but not in LC3A-II, correlated with elevated levels of autophagic vesicles monitored
either by electron microscopy or rat GFP-LC3 transfection in response to autophagy-inducing
stress (Corcelle E, Mograbi B, personal communication). This supports the important notion
that the LC3 isoforms display different functions, and we therefore advise anti-LC3B for
western blotting and immunofluorescence experiments rather than anti-LC3A.
One additional point concerns the monitoring of Atg12—Atg5 conjugation, which has been
used in some studies to measure autophagy. In some mammalian cells it appears that essentially
all of the Atg5 and Atg12 proteins exist in the conjugated form and the expression levels do
not change, at least during short-term starvation.37,38 Therefore, monitoring Atg12—Atg5
conjugation per se may not be a useful method for following the induction of autophagy. It is
worth noting, however, that in some cell lines free Atg5 can be detected,39 suggesting that the
amount of free Atg5 may be cell line-dependent. One final parameter that may be considered
is that the total amount of the Atg12—Atg5 conjugate may increase following prolonged
starvation as has been observed in hepatocytes and fibroblasts (Cuervo AM, personal
communication).
Finally, we would like to point out one general issue with regard to any assay is that it could
introduce some type of stress, for example, mechanical stress due to lysis, temperature stress
due to heating or cooling a sample, or oxidative stress on a microscope slide, which could lead
to potential artifacts. This point is not intended to limit the use of any specific methodology,
but rather to point out there are no perfect assays. Therefore, it is important to verify that the
positive (e.g., rapamycin treatment) and negative (e.g., inhibitor treatment) controls behave as
expected in any assays being utilized.
3. Fluorescence microscopy
LC3B (hereafter referred to as LC3), or the protein tagged at its N terminus with a fluorescent
protein such as GFP, GFP-LC3, has been used to monitor autophagy through indirect
immunofluorescence (Fig. 3A) or direct fluorescence microscopy (Fig. 3B), measured as an
increase in punctate LC3 or GFP-LC3.40 The detection of GFP-LC3/Atg8 is also useful for in
vivo studies using transgenic organisms such as Caenorhabditis elegans,41 Dictyostelium
discoideum,42 Drosophila melanogaster,43,44 Arabidopsis thaliana45 and mice.30 It is also
possible to use anti-LC3 antibodies for immunocytochemistry or immunohistochemistry,46–
48 procedures that have the advantages of detecting the endogenous protein, obviating the need
for transfection and transgenesis, as well as avoiding potential artifacts resulting from
overexpression. Monitoring the endogenous protein, however, obviously depends on the ability
to detect it in the system of interest. If the endogenous amount is below the level of detection,
the use of an exogenous construct is warranted. In this case, it is important to consider the use
of stable transformants versus transient transfections. Stable transformants may have reduced
background resulting from the lower protein expression, and there is also the advantage of
eliminating artifacts resulting from recent exposure to transfection reagents. Furthermore, with
stable transformants more cells can be easily analyzed because nearly 100% of the population
will express tagged LC3. On the other hand, one disadvantage of stable transfectants is that
the integration sites cannot always be predicted, and expression levels may not be optimal.
Furthermore, an important advantage of transient transfection is that this approach is better for
examining the immediate effects of the transfected protein on autophagy. In addition, a double
transfection can be used (e.g., with GFP-LC3 and the protein of interest) to visually tag the
cells that express the protein being examined, an approach that may be more problematic with
stable transfectants. In conclusion, there is no simple rule for the use of stable versus transient
transfections. When stable transfections are utilized, it is worthwhile screening for clones that
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give the best signal to noise ratio, and when transient transfections are used, it is worthwhile
optimizing the GFP-LC3 DNA concentration to give the best signal to noise ratio.
Optimization, together with including the appropriate controls, will help overcome the effects
of the inherent variability in these analyses.
An additional use of GFP-LC3 is to monitor co-localization with a target during autophagy-
related processes such as organelle degradation or the sequestration of pathogenic microbes.
49–51 For observing autophagy in C. elegans, it is best to use an integrated version of GFP-
LC3 (GFP:LGG-1; Fig. 4) rather than an extra-chromosomal construct because the latter shows
variable expression among different animals (Kang C, personal communication). In addition,
with the integrated version it is still possible to perform a western blot analysis for lipidation.
52 Finally, we point out the increasing availability of instruments that are capable of nanoscale
resolution for GFP-based microscopy, which will further enhance the value and possibilities
afforded by this technology.53
Yeast Atg18 is required for both macroautophagy (i.e., non-specific sequestration of
cytoplasm) and autophagy-related processes (e.g., the cytoplasm to vacuole targeting pathway,
54,55 specific organelle degradation,56 and autophagic elimination of invasive microbes57–
61).62 A recent study shows that the human homologue of Atg18 (WIPI-1) accumulates at
LC3-positive membrane structures when autophagy is induced, and the increase in Atg18
puncta correlates with elevated levels of LC3-II.63 Endogenous levels of Atg18 can also be
detected by indirect fluorescence microscopy and immunoelectron microscopy, and the
distribution of transfected GFP-Atg18 appears similar. Accordingly, Atg18 puncta can be
assessed as an alternative to LC3. With regard to other Atg proteins, Atg9 also displays partial
co-localization with GFP-LC3.64 Monitoring the localization of Atg9 has not been used
extensively in higher eukaryotes, but this protein displays the same type of dependence for
cycling on Atg1/Ulk1 as seen in yeast,64,65 suggesting that it is possible to follow this protein
as an indication of Atg1 function. Finally, Atg8/LC3 is the only protein known to remain
associated with the autophagosome in higher eukaryotes, but additional proteins, in particular
Atg5, Atg12 and Atg16, associate with the phagophore and have been detected by fluorescence
or immunofluorescence.37,38
Cautionary notes—Although analysis of fluorescent GFP-LC3 is a useful approach, it is
more tedious to quantify autophagy by measuring puncta of GFP-LC3 (or LC3 by
immunofluorescence), than by monitoring LC3-II by western blot. Ideally, it is preferable to
include both assays and to compare the two sets of results. In addition, if GFP-LC3 is being
quantified, it is preferable to determine the number of puncta corresponding to GFP-LC3 on a
per cell basis rather than simply the total number of cells displaying puncta. This latter point
is critical because even cells in nutrient-rich conditions display some basal level of GFP-LC3
puncta, unless they are lacking autophagy-related genes (and even in the latter case it is possible
to get puncta of GFP-LC3 depending on the specific conditions) (Fig. 3B). There are, however,
practical issues with counting puncta manually and reliably, especially if there are large
numbers per cell (although this may be more accurate than relying on a software program, in
which case it is important to ensure that only appropriate dots are being counted). Also, when
autophagosome-lysosome fusion is blocked, larger autophagosomes are detected, possibly due
to autophagosome-autophagosome fusion. In many cell types it may be possible to establish a
cut-off value for the number of puncta per cell in conditions of “low” and “high” autophagy.
66 This can be tested empirically by exposing cells to autophagy-inducing and -blocking
agents. Thus, cell populations showing significantly greater proportions of cells with
autophagosome numbers higher than the cut-off in perturbation conditions compared to the
control cells could provide quantitative evidence of altered autophagy. It is then possible to
score the population as the percentage of cells displaying numerous autophagosomes. This
approach will only be feasible if the background number of puncta is relatively low, and, in
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this case, it is particularly important to count a large number of cells (probably on the order of
fifty or more, preferably in at least three different trials, depending on the particular system
and experiment).
To allow comparisons by other researchers attempting to repeat these experiments, it is critical
that the authors also specify the baseline number of puncta that are used to define “normal” or
“low” autophagy. Furthermore, the cells should also be counted using unbiased procedures
(e.g., using a random start point followed by inclusion of all cells at regular intervals), and
statistical information should be provided for both baseline and altered conditions, as these
assays can be highly variable. One possible method to obtain unbiased counting of GFP-LC3
puncta in a large number of cells is to perform multispectral imaging flow cytometry. This
method allows characterization of single cells within a population by assessing a combination
of morphology and immunofluorescence patterns, thereby providing statistically meaningful
data.67 An additional caution is that size determinations can be problematic by fluorescence
microscopy unless careful standardization is carried out.68 Furthermore, it is not clear that
different sizes of GFP-LC3 puncta correlate with levels of autophagy.
One possible control to determine background levels of puncta is to examine fluorescence from
untagged GFP. An important caveat in the use of GFP-LC3 is that this chimera can associate
with aggregates, especially when expressed at high levels in the presence of aggregate-prone
proteins, which can lead to a misinterpretation of the results.69 Of note, GFP-LC3 can associate
with ubiquitinated protein aggregates;70 however, this does not occur if the GFP-LC3 is
expressed at low levels (Rubinsztein DC, unpublished observations). These aggregates have
been described in many systems, and are also referred to as Aggresome-Like Induced Structures
or ALIS,70,71 dendritic cell ALIS,72 p62 bodies/sequestosomes73 and inclusions. Inhibition
of autophagy in vitro and in vivo leads to the accumulation of these aggregates, suggesting a
role for autophagy in mediating their clearance.70,71,74,75 The adaptor protein p62 is required
for the formation of ubiquitinated protein aggregates in vitro.73 In this case, the interaction of
p62 with both ubiquitinated proteins and LC3 is thought to mediate delivery of these aggregates
to the autophagy system.76 Many cellular stresses can induce the formation of aggregates,
including transfection reagents.70 Moreover, calcium phosphate transfection of COS7 cells or
lipofectamine transfection of MEFs (Pinkas-Kramarski R, personal communication) or
neuronal cells (Chu CT, personal communication) transiently increases basal levels of GFP-
LC3 puncta and/or the amount of LC3-II. One solution is to examine GFP-LC3 puncta in cells
stably expressing GFP-LC3; however, as transfection-induced increases in GFP-LC3 puncta
and LC3-II are often transient, another approach is to use cells transfected with GFP, and cells
subjected to a mock time-matched transfection as background (negative) controls. A lipidation-
defective LC3 mutant where glycine 120 is mutated to alanine is targeted to these aggregates
independently of autophagy (likely via its interaction with p62, see above) and as a result this
mutant can serve as another valuable control.70
Ubiquitinated protein aggregate formation and clearance appear to represent a cellular
recycling process. Aggregate formation can occur when autophagy is either inhibited or when
its capacity for degradation is exceeded by the formation of proteins delivered to the aggregates.
In principle, formation of GFP-LC3-positive aggregates represents a component of the
autophagy process. However, the formation of ubiquitinated GFP-LC3-positive protein
aggregates does not directly reflect either the induction of autophagy (or autophagosome
formation), or flux through the system. Indeed, formation of ubiquitinated protein aggregates
can occur in autophagy-deficient cells.70 Therefore it should be remembered that GFP-LC3
puncta likely represent a mix of ubiquitinated protein aggregates in the cytosol, ubiquitinated
protein aggregates within autophagosomes and more “conventional” phagophores and
autophagosomes bearing other cytoplasmic cargo. Moreover, a recent report shows that
treatment with saponin and other detergents can provoke artifactual GFP-LC3 puncta
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formation.77 Saponin treatment has been used to reduce background fluorescence under
conditions where no aggregation of GFP-LC3 is detected in both hepatocytes,78 and in GFP-
LC3 stably-transfected HEK-293 cells (Tooze S, unpublished data); however, controls need
to be included in such experiments in light of these findings. In general, it is preferable to
include additional assays that measure autophagy rather than relying solely on monitoring GFP-
LC3. In addition, we recommend that researchers validate their assays at the start by
demonstrating the absence or reversal of GFP-LC3 puncta formation in cells treated with
pharmacological or RNA interference-based autophagy inhibitors. For example, 3-
methyladenine (3-MA) is commonly used to inhibit starvation- or rapamycin-induced
autophagy.
Another general limitation of the GFP-LC3 assay is that it requires a system amenable to either
transfection or transgenesis (e.g., infection). Accordingly, the use of GFP-LC3 in primary non-
transgenic cells is more challenging. Here again, controls need to be included to verify that the
transfection protocol itself does not artifactually induce GFP-LC3 puncta or cause LC3
aggregation. Furthermore, transfection should be performed with low levels of constructs, and
the transfected cells followed to determine (1) when sufficient expression for detection is
achieved, and (2) that during the time frame of the assay, basal GFP-LC3 puncta remain
appropriately low. In addition, the demonstration of a reduction in the number of induced GFP-
LC3 puncta under conditions of autophagy inhibition is helpful. For some primary cells,
delivering GFP-LC3 to precursor cells by infection with recombinant lentivirus,
adenovirus79 or retrovirus, and subsequent differentiation into the cell type of interest, is a
powerful alternative to transfection of the already differentiated cell type.80
An additional consideration is that transfection protocols, or viral infection, activate stress
pathways in some cells and possibly induce autophagy, again emphasizing the importance of
appropriate controls, such as control viruses expressing GFP.78 When carrying out
transfections it may be necessary to alter the protocol depending on the background. In addition,
changing the medium and waiting 24 to 48 hours after the transfection can help to reduce the
background level of GFP-LC3 puncta that is due to the transfection reagent (Colombo MI,
personal communication). When using an mCherry-GFP-p62 double tag (see below under
Tandem RFP-GFP fluorescence microscopy) in transient transfections it is best to wait 48
hours after transfection to reduce the level of aggregate formation and potential inhibition of
autophagy (Johansen T, personal communication).
Finally, although LC3-II is primarily membrane associated, it is not necessarily associated with
autophagosomes as is often assumed; the protein is also found on phagophores, the precursors
to autophagosomes. In addition, the site of LC3 conjugation to PE is not known and levels of
Atg8—PE/LC3-II can increase even in autophagy mutants that cannot form autophagosomes.
81 One method that can be used to examine LC3-II membrane association is differential
extraction in Triton X-114, which can be used with mammalian cells.79 Another approach is
to examine co-localization of LC3 with Atg5 (or other Atg proteins); the Atg12—Atg5
conjugate does not remain associated with autophagosomes so co-localized structures would
correspond to phagophores. Importantly, we stress again that numbers of GFP-LC3 puncta,
similar to steady state LC3-II levels, reflect only a snapshot of the numbers of autophagy-
related structures (e.g., autophagosomes) in a cell, and not autophagic flux.
With regard to detection of Atg18 or GFP-Atg18, it has not been demonstrated whether Atg18
puncta can be detected in systems other than human cells, and the level of puncta formation is
cell context-dependent.63 Additionally, Atg18 has not been detected on the completed (mature)
autophagosome, so it may only decorate the phagophore. Accordingly, the formation of Atg18
puncta may only be useful to monitor autophagy induction and not flux.
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4. TOR and Atg1 kinase activity
TOR complex I (TORC1) negatively regulates autophagy in a transcription-independent
manner downstream of protein kinase B. In most systems, inhibition of TOR leads to induction
of autophagy. TORC1 activity can be monitored by following the phosphorylation of its target
protein(s) or downstream effectors, such as p70S6 kinase or the S6 protein.82,83 For p70S6
kinase, it is important to examine phosphorylation at threonine 389, which is a direct target of
TOR and is rapamycin-sensitive; the C-terminal phosphorylation sites do not always correlate
with TOR activation (Murphy LO, personal communication). Accordingly, it is better to
quantify p70S6 kinase activity in vitro, but this requires greater effort. A decrease in TORC1
activity can lead to autophagy induction, however, it is not a direct measurement. In contrast,
in vitro Atg1 kinase activity towards an exogenous substrate appears to increase when
autophagy is induced.84 In yeast, and presumably in other organisms, it is possible to measure
Atg1 kinase activity to verify the induction of autophagy.
Cautionary notes—There are TOR-independent mechanisms that induce autophagy.85–
88 Thus, it is necessary to verify that the pathway being analyzed displays TOR-dependent
inhibition. At present, the use of Atg1 kinase activity as a tool to monitor autophagy is limited
because an authentic substrate has not been characterized; the current assays rely on in vitro
phosphorylation of the artificial substrate myelin basic protein. When a physiological substrate
(s) of Atg1 is identified it will be possible to follow its phosphorylation in vivo as is done with
analyses for TOR.
5. Transcriptional regulation
The induction of autophagy in certain scenarios is accompanied by an increase in the mRNA
levels of certain autophagy genes, such as Atg8/LC389 and Atg12.90 Thus, assessing the levels
of LC3 mRNA by northern blot or qRT-PCR may provide correlative data relating to the
induction of autophagy. It is not clear if these changes are sufficient to induce autophagy,
however, and therefore these are not direct measurements. Of note, large changes in Atg gene
transcription just prior to Drosophila melanogaster salivary gland cell death (that is
accompanied by an increase in autophagy) are detected in Atg2, Atg4, Atg5 and Atg7, whereas
there is no significant change in Atg8a or Atg8b.91,92 However, transcriptional upregulation
of Drosophila melanogaster Atg8a and Atg8b is observed in fat bodies following induction of
autophagy at the end of larval development,93 and an increase in Drosophila melanogaster
Atg8b is observed in cultured Drosophila melanogaster l(2)mbn cells following starvation
(Gorski S, personal communication).
Cautionary notes—Most of the Atg genes do not show significant changes in mRNA levels
when autophagy is induced. Even increases in LC3 mRNA can be quite modest and are cell
type- and organism-dependent.94 In addition, it is generally better to follow protein levels
because that is the ultimate readout that is significant with regard to the initiation and
completion of autophagy, although Atg protein amounts do not always change significantly
and the extent of increase is again cell type- and tissue-dependent. Finally, changes in
autophagy protein levels are not sufficient evidence of autophagy induction, and must be
accompanied by additional assays as described herein.
B. Monitoring Autophagy by Flux Measurements
Autophagy includes not just the increased synthesis or lipidation of Atg8/LC3, or an increase
in the formation of autophagosomes, but most importantly flux, or flow, through the entire
system, including lysosomes or the vacuole. Therefore, autophagic substrates need to be
monitored to verify that they have reached this organelle, and, when appropriate, degraded.
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1. Autophagic protein degradation
Protein degradation assays represent a well-established methodology for measuring autophagic
flux, and they allow good quantification. The general strategy is first to label cellular proteins
by incorporation of a radioactive amino acid (e.g., [14C]-leucine or [14C]-valine), preferably
for a long time to achieve sufficient labeling of the long-lived proteins that best represent
autophagic substrates, and then to follow this with a long cold-chase so that the assay starts
well after labeled short-lived proteins are degraded. Next, the time-dependent release of acid-
soluble radioactivity from the labeled protein in intact cells or perfused organs is measured.
2,95 A considerable fraction of the measured degradation will, however, be non-autophagic,
and thus one should also measure, in parallel, cell samples treated with autophagy-suppressive
concentrations of 3-MA or amino acids; these values are then subtracted from the total. The
complementary approach of using compounds that block other degradative pathways, such as
proteasome inhibitors, may cause unexpected results due to crosstalk among the degradative
systems. For example, blocking proteasome function may activate autophagy.96–98 Thus,
when using inhibitors it is critical to know whether the inhibitors being used alter autophagy,
in the particular cell type and context being examined. In addition, because 3-MA could have
some autophagy-independent effects in particular settings it is advisable to verify that the 3-
MA-sensitive degradation is also sensitive to general lysosomal inhibitors (such as ammonium
chloride or leupeptin).
Another assay that could be considered relies on the limited proteolysis of a betaine
homocysteine methyltransferase (BHMT) fusion protein. Previous studies show that the 44
kDa full-length BHMT protein is cleaved in hepatocytic lysosomes in the presence of leupeptin
to generate a 32 kDa fragment.99,100 Accumulation of the 32 kDa species is time-dependent
and is blocked by treatment with autophagy inhibitors. A modified version of this marker,
GST-BHMT, can be expressed in other cell lines where it behaves similar to the wild-type
protein (Mercer C, Kaliappan A, Dennis PB, personal communication). Other substrates may
be considered for similar types of assays. For example, the neomycin phosphotransferase II-
GFP (NeoR-GFP) fusion protein is a target of autophagy.101 Transfection of lymphoblastoid
cells with a plasmid encoding NeoR-GFP followed by incubation in the presence of 3-MA
leads to an accumulation of the NeoR-GFP protein as measured by flow cytometry.102
Cautionary notes—Measuring the degradation of long-lived proteins requires prior
radiolabeling of the cells (and subsequent separation of acid-soluble from acid-insoluble
radioactivity), and although the labeling can be done with relative ease in cultured cells, such
pulse-chase experiments are not possible in animals, although they can be done in perfused
organs. In cells, it is also possible to measure the release of an unlabeled amino acid by
chromatographic methods, thereby obviating the need for prelabeling.103 In either case, one
potential problem is that the released amino acid may be further metabolized. For example,
branched chain amino acids are good indicators of proteolysis in hepatocytes, but not in muscle
cells where they are further oxidized (Meijer AJ, personal communication). Furthermore, the
amino acid can be reincorporated into protein; for this reason, such experiments can be carried
out in the presence of cycloheximide, but this raises additional concerns (see Turnover of
autophagic compartments below). In the case of labeled amino acids, a non-labeled chase is
added where the tracer amino acid is present in excess (being cautious to avoid using an amino
acid that inhibits autophagy), or by use of single pass perfused organs or superfused cells.
104,105 The perfused organ system also allows for testing the reversibility of effects on
proteolysis and the use of autophagy-specific inhibitors in the same experimental preparation,
which are crucial controls for proper assessment.
If the autophagic protein degradation is low (as it will be in cells in replete medium), it may
be difficult to measure it reliably above the relatively high background of non-autophagic
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degradation. It should also be noted that the usual practice of incubating the cells under
“degradation conditions,” that is, in a saline buffer, indicates the potential autophagic
capacity (maximal attainable activity) of the cells rather than the autophagic activity that
prevails in vivo or under rich culture conditions. Finally, inhibition of a particular degradative
pathway is typically accompanied by an increase in a separate pathway as the cell attempts to
compensate for the loss of degradative capacity.98,106 This compensation might interfere with
control measurements under conditions that attempt to inhibit macroautophagy; however, as
the latter is the major degradative pathway, the contributions of other types of degradation over
the course of this type of experiment are most often negligible.
2. Turnover of LC3-II
Autophagic flux can be measured by inferring LC3-II turnover by western blot (Fig. 2)31 in
the presence and absence of lysosomal degradation. Preventing lysosomal degradation can be
achieved through the use of protease inhibitors (e.g., leupeptin and E64d) or drugs such as
bafilomycin A1 that alter the lysosomal pH,107 or by treatment with agents that block fusion
of autophagosomes with lysosomes.
One of the most recent additions to methodologies for monitoring autophagy relies on the
observation that a subpopulation of LC3-II exists in a cytosolic form (LC3-IIs) in some cell
types.108 The amount of cytosolic LC3-IIs and the ratio between LC3-I and LC3-IIs appears
to correlate with changes in autophagy and provides a more accurate measure of autophagic
flux than ratios based on the total level of LC3-II.108 The validity of this method has been
demonstrated by comparing autophagic proteolytic flux in rat hepatocytes and hepatoma cells.
One advantage of this approach is that it does not require the presence of autophagic or
lysosomal inhibitors to block the degradation of LC3-II.
Cautionary notes—The main caveat regarding the measurement of LC3-IIs/LC3-I is that it
is not yet known whether this method is generally applicable to other cell types, and a soluble
form of LC3-II is not observed in many standard cell types including HeLa, HEK293 and PC12.
In addition, the same concerns apply regarding detection of LC3-I by western blotting. It should
be noted that the LC3-IIs/LC3-I ratio must be analyzed using the cytosolic fractions rather than
the total homogenates. In addition, the same caveats mentioned above regarding the use of LC3
for qualitatively monitoring autophagy also apply to the use of this marker for following flux.
The use of a radioactive pulse-chase analysis provides an alternative to lysosomal protease
inhibitors,29 although such inhibitors should still be used to verify that degradation is
lysosome-dependent. In addition, drugs must be used at concentrations and for time spans that
are effective in inhibiting fusion or degradation, but that do not provoke cell death. Thus, these
techniques may not be practical in all cell types or in tissues from whole organisms where the
use of protease inhibitors is problematic, and where pulse labeling requires artificial short-term
culture conditions that may induce autophagy.
It may not be absolutely necessary to follow LC3-II turnover if other substrates are being
monitored simultaneously. For example, an increase in LC3-II levels in combination with the
lysosomal (or ideally autophagy-specific) removal of an autophagic substrate (such as a polyQ-
expanded protein for researchers studying neurodegeneration, or an organelle109) that is not
a good proteasomal substrate provides an independent assessment of autophagic flux.
3. GFP-Atg8/LC3 lysosomal delivery and proteolysis
GFP-LC3B (GFP-LC3) has also been used to follow flux. First, when GFP-Atg8 or GFP-LC3
is delivered to a lysosome the Atg8/LC3 part of the chimera is sensitive to degradation, whereas
the GFP protein (although not necessarily GFP fluorescence) is relatively resistant to
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hydrolysis. Therefore, the appearance of free GFP on western blots can be used to monitor
lysis of the inner autophagosome membrane and breakdown of the cargo (Fig. 5).110–112 The
movement of GFP-LC3 to lysosomes also can be monitored by fluorescence microscopy,
although the GFP fluorescent signal is more sensitive to acidic pH than other fluorophores. In
either case, it can be problematic to use GFP fluorescence to follow flux, as new GFP-LC3 is
being synthesized. A potential solution to this problem for following fluorescence is to use a
photoactivatable version of the fluorescent protein,113 which allows this assay to be performed
essentially as a pulse/chase analysis. Another alternative is to follow flux using GFP-LC3
fluorescence by adding lysosomal protease inhibitors to cells expressing GFP-LC3 and
monitoring changes in the number of puncta. In this case, the presence of lysosomal inhibitors
should increase the number of GFP-LC3-positive structures, and the absence of an effect on
the total number of GFP-LC3 puncta or on the percentage of cells displaying numerous puncta
is indicative of a defect(s) in autophagic flux.114 The combination of protease inhibitors (to
prevent the degradation of GFP) or compounds that modify lysosomal pH such as ammonium
chloride or chloroquine, or drugs such as bafilomycin A1 along with compounds that block
fusion of autophagosomes with lysosomes (e.g., vinblastine) may be most effective in
preventing lysosome-dependent decreases in GFP-LC3 puncta. However, because the stability
of GFP is affected by lysosomal pH, we advise the use of protease inhibitors whether or not
lysosomotropic compounds or fusion inhibitors are included. Finally, a new method was
recently developed utilizing the fluorescence activated cell sorter to allow quantitative analysis
of GFP-LC3 turnover (Shvets E, Fass E, Elazar Z, personal communication).
Cautionary notes—The main limitation of the GFP-LC3 processing assay is that it seems
to depend on cell types and culture conditions (Hosokawa N, Mizushima N, unpublished data).
Apparently, GFP is more sensitive to mammalian lysosomal hydrolases than the degradative
milieu of the yeast vacuole. Alternatively, the lower pH of lysosomes relative to that of the
vacuole may contribute to differences in detecting free GFP. Therefore, if this method is used
it should be accompanied by immunoblotting including controls to address the stability of non-
lysosomal GFP such as GFP-LC3-I. Along these lines, a caution concerning the use of the
eGFP fluorescent protein for microscopy is that this fluorophore has a relatively neutral pH
optimum for fluorescence,115 so that its signal may diminish quickly at a reduced pH. Thus,
it may be preferable to use an alternate fluorophore such as red fluorescent protein (RFP) or
mCherry, which retain fluorescence even at acidic pH.116 Another alternative to RFP or
mCherry is to use the Venus variant of YFP, which is brighter than mRFP and less sensitive
to pH than GFP.117 The pH optimum of eGFP is important to consider when using GFP-LC3
constructs, as the original GFP-LC3 marker40 uses the eGFP variant, which may result in a
reduced signal upon the formation of amphisomes or autolysosomes. An additional caveat
when using the photoactivatable construct PA-GFP115 is that the process of activation by
photons may induce DNA damage, which could, in turn, elicit induction of autophagy. Finally,
GFP is relatively resistant to denaturation, and boiling for 5 min may be needed to prevent
folded protein from being trapped in the stacking gel during SDS-PAGE.
4. p62 western blot
In addition to LC3, it is also possible to use p62/SQSTM1 as a marker, at least in certain settings.
33 The p62 protein serves as a link between LC3 and ubiquitinated substrates.118 p62 becomes
incorporated into the completed autophagosome and is degraded in autolysosomes (Fig. 6A).
A recent study shows that inhibition of autophagy correlates with increased levels of p62,
suggesting that steady state levels of this protein reflect the autophagic status.119,120
Interestingly, another report shows that p62 is involved in inclusion body formation and that
loss of p62 attenuates the liver injury that results from a deficiency in autophagy.121 In contrast,
loss of p62 had little effect on neuronal degeneration, suggesting a cell-type specific nature to
inclusion body-related pathologies.
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Cautionary notes—One problem with p62 is that it is presently not known if this protein is
a general marker for autophagy, although it binds strongly to LC3 as well as to ubiquitinated
substrates. In addition, it is most easily used to assess the down-regulation rather than the
induction of autophagy (i.e., p62 levels only increase when autophagy is blocked; Fig. 6B).
For example, there is no obvious difference in p62 amounts after 30 minutes of autophagy
induction, whereas a change in LC3-II can be detected by this time.33 Furthermore, it is
necessary to examine endogenous p62 because overexpression of this protein leads to the
formation of protein inclusions. In fact, even endogenous p62 becomes Triton X-100-insoluble
in the presence of protein aggregates and when autophagic degradation is inhibited; thus, results
with this protein are often context-dependent. In addition, p62 participates in proteasomal
degradation, and its level may also increase when the proteasome is inhibited.122 Finally, p62
may be transcriptionally upregulated under certain conditions,123 further complicating the
interpretation of results. In conclusion, although analysis of p62 can assist in assessing the
impairment of autophagy, we do not recommend using p62 alone to monitor flux.
5. Autophagic sequestration assays
Autophagic activity can also be monitored by the sequestration of autophagic cargo, using
either an (electro)injected, inert cytosolic marker such as [3H]raffinose,124 or an endogenous
cytosolic protein such as lactate dehydrogenase,125 in the latter case along with treatment with
a proteinase inhibitor (e.g., leupeptin) to prevent intralysosomal degradation of the protein
marker. The assay simply measures the transfer of cargo from the soluble (cytosol) to the
insoluble (sedimentable) cell fraction (which includes autophagic compartments), with no need
for a sophisticated subcellular fractionation (a filtration assay would presumably work just as
well as centrifugation, although it would be necessary to verify that the filtration membrane
does not destroy the integrity of the post-nuclear supernatant compartments). The cargo marker
can be quantified by an enzymatic assay, or by western blotting. In principle, any intracellular
component can be used as a cargo marker, but cytosolic enzymes having low sedimentable
backgrounds are preferable. Membrane-associated markers are less suitable, and proteins such
as LC3, which are part of the sequestering system itself, will have a much more complex
relationship to the autophagic flux than a pure cargo marker such as lactate dehydrogenase.
Sequestration assays can be designed to measure flux through individual steps of the autophagy
pathway. For example, microtubule inhibitors such as vinblastine will block autophagosome-
lysosome fusion, and intralysosomally degraded sequestration probes such as [14C]lactate will
mark only prelysosomal compartments in cells treated with this inhibitor,126 and these have
been used to obtain background control data for monitoring of the overall autophagic pathway
(autophagic lactolysis).127 One caveat, however, is that some of these inhibitors promote
sequestration through an unknown mechanism (see Autophagy inhibitors and inducers).
A variation of this approach applicable to mammalian cells includes live cell imaging.
Autophagy induction is monitored as the movement of cargo, such as mitochondria, to GFP-
LC3-colocalizing compartments, and then fusion/flux is measured by delivery of cargo to
lysosomal compartments.79,128 In addition, sequestration of fluorescently tagged cytosolic
proteins into membranous compartments can be measured, as fluorescent puncta become
resistant to the detergent digitonin.129
Cautionary notes—The electro-injection of radiolabeled probes is technically demanding,
but the use of an endogenous cytosolic protein probe is very simple and requires no pretreatment
of the cells other than with a protease inhibitor. Another concern with electro-injection is that
it can affect cellular physiology, so it is necessary to verify that the cells behave properly under
control situations such as amino acid deprivation. An alternate approach for incorporating
exogenous proteins into mammalian cell cytosol is to use “scrape-loading,” a method that
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works for cells that are adherent to tissue culture plates.130 Finally, these assays work well
with hepatocytes but may be problematic with other cell types, and it can be difficult to load
the cell while retaining the integrity of the compartments in the post-nuclear supernatant (Tooze
S, unpublished results). General points of caution to be addressed with regard to live cell
imaging relate to photo-bleaching of the fluorophore, cell injury due to repetitive imaging,
autofluorescence in tissues containing lipofuscin, and the pH sensitivity of the fluorophore.
6. Turnover of autophagic compartments
Inhibitors of autophagic sequestration (e.g., amino acids, 3-MA or wortmannin) can be used
to monitor the disappearance of autophagic elements (phagophores, autophagosomes,
autolysosomes) to estimate their half-life by electron microscopy morphometry/stereology.
The turnover of the autophagosome or the autolysosome will be differentially affected if fusion
or intralysosomal degradation is inhibited.131–134 The duration of such experiments is usually
only a few hours; therefore, long-term side effects or declining effectiveness of the inhibitors
can be avoided. It should be noted that fluorescence microscopy has also been used to monitor
the half-life of autophagosomes, monitoring GFP-LC3 in the presence and absence of
bafilomycin A1 or following GFP-LC3 after starvation and recovery in amino acid-rich
medium.107
Cautionary notes—The inhibitory effect must be strong and the efficiency of the inhibitor
needs to be tested under the experimental conditions to be employed. Cycloheximide is
frequently used as an autophagy inhibitor, but this is problematic because of the many potential
indirect effects. For example, cycloheximide decreases the efficiency of protein degradation
in several cell types (Cuervo AM, personal communication). In addition, at high concentrations
(in the millimolar range) cycloheximide inhibits complex I of the mitochondrial respiratory
chain,135 but this is not a problem, at least in hepatocytes, at low concentrations (10–20 μM)
that are sufficient to prevent protein synthesis (Meijer AJ, personal communication).
7. Autophagosome-lysosome colocalization and dequenching assay
Another method to demonstrate the convergence of the autophagic pathway with a functional
degradative compartment is to incubate cells with the bovine serum albumin derivative de-
quenched (DQ)-BSA that has been labeled with the red-fluorescent BODIPY TR-X dye; this
conjugate will accumulate in lysosomes. The labeling of DQ-BSA is so extensive that the
fluorophore is self-quenched. Proteolysis of this compound results in de-quenching and the
release of brightly fluorescent fragments. Thus, the use of DQ-BSA is useful for detecting
intracellular proteolytic activity as a measure of a functional lysosome (Colombo MI, personal
communication). Furthermore, DQ-BSA labeling can be combined with GFP-LC3 to monitor
colocalization and thus visualize the convergence of autophagosomes with a functional
degradative compartment. This method can also be used to visualize fusion events in real time
experiments by confocal microscopy (live cell imaging). Along similar lines, other approaches
for monitoring convergence are to follow the colocalization of RFP-LC3 and LysoSensor
Green (Bains M, Heidenreich KA, personal communication) or tagged versions of LC3 and
LAMP-1 (Macleod K, personal communication) as a measure of the fusion of autophagosomes
with lysosomes.
Cautionary notes—Some experiments require the use of inhibitors (e.g., 3-MA or
wortmannin) or overexpression of proteins (e.g., Rab7 dominant negative mutants) that may
also affect the endocytic pathway or the delivery of DQ-BSA to lysosomes. In this case, the
lysosomal compartment can be labeled with DQ-BSA overnight before treating the cells with
the drugs or prior to the transfection.
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8. Sequestration and processing assays in plants
The fluorophore of the red fluorescent protein shows a relatively high stability under acidic
pH conditions. Thus, chimeric RFP fusion proteins that are sequestered within autophagosomes
and delivered to the plant vacuole can be easily detected by fluorescence microscopy.
Furthermore, fusion proteins with some versions of RFP tend to form intracellular aggregates,
allowing the development of a visible autophagic assay for plant cells.136 For example, fusion
of cytochrome b5 and the original (tetrameric) RFP generate an aggregated cargo protein that
displays cytosolic puncta of red fluorescence and, following vacuolar delivery, diffuse staining
throughout the vacuolar lumen. This system allows autophagy to be monitored through
fluorescence microscopy with minimum damage to intact plant cells. In addition, the size
difference between the intact and processed cargo protein allows the quantification of
autophagic degradation through the detection of RFP after separation of total protein by gel
electrophoresis, similar to the GFP-Atg8/LC3 processing assay described above. As with other
systems, autophagosome formation in plants can also be monitored through the use of
fluorescent protein fusions to Atg8, and electron microscopy (Fig. 7).
In some systems, including fungi and plants, the size of the vacuole is sufficiently large such
that fusion of the autophagosome results in the release of the inner vesicle into the organelle
lumen; the resulting single-membrane vesicle is termed an autophagic body (Fig. 8). The
accumulation of autophagic bodies can be detected by light microscopy in cells that lack
vacuolar hydrolase activity (e.g., the pep4Δ yeast mutant) or in the presence of inhibitors that
interfere with hydrolase activity (e.g., PMSF or concanamycin). Using Nomarski optics
(differential interference contrast) it is easy to distinguish and quantify yeast vacuoles that lack
autophagic bodies from those that have accumulated them, and the same is true for plants.
Cautionary notes: Although the detection of vacuolar RFP can be applied to both plant cell
lines and to intact plants, it is not practical to measure RFP fluorescence in intact plant leaves,
due to the very high red fluorescence of chloroplasts. Furthermore, different autophagic
induction conditions cause differences in protein synthesis rates; thus, special care should be
taken to monitor the efficiency of autophagy by quantifying the intact and processed cargo
proteins. With regard to autophagic body accumulation, it is difficult to quantify their number
and/or volume, although their presence or absence can be examined by light or electron
microscopy. In addition, the accumulation of autophagic bodies requires the inhibition of
vacuolar hydrolase activity. Therefore, to demonstrate turnover the assay must be performed
either in the absence and presence of appropriate inhibitors or in a strain with a deletion in a
gene encoding a vacuolar hydrolase(s). Otherwise, accumulation of autophagic bodies could
instead indicate a defect in the lysis/degradation step of autophagy. Finally, this method is not
well suited for systems other than plants or fungi because lysosomes are too small for detection
by standard (i.e., non-fluorescence) light microscopy, and fusion with autophagosomes does
not generate autophagic bodies (Fig. 8).
9. Tandem RFP-GFP fluorescence microscopy
A new assay that can be used to monitor flux relies on the use of a tandem monomeric RFP-
GFP-tagged LC3 (tfLC3; Fig. 9).116 The GFP signal is sensitive to the acidic and/or proteolytic
conditions of the lysosome lumen, whereas mRFP is more stable. Therefore, colocalization of
both GFP and RFP fluorescence indicates a compartment that has not fused with a lysosome,
such as the phagophore or an autophagosome. In contrast, an mRFP signal without GFP
corresponds to an amphisome or autolysosome. Other fluorophores such as mCherry are also
suitable instead of mRFP.73 One of the major advantages of this method is that it enables
simultaneous estimation of both the induction of autophagy and flux through autophagic
compartments in essentially native conditions, without requiring any drug treatment.
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Cautionary notes—This is a new assay that has not been tested in a wide range of cell types.
Accordingly, the sensitivity and the specificity of the method must be verified independently
until this method has been tested more extensively.
10. Tissue fractionation
The study of autophagy in the organs of larger animals, in large numbers of organisms with
very similar characteristics, or in tissue culture cells provides an opportunity to use tissue
fractionation techniques as has been possible with glucagon-induced autophagy in rat liver.
137–141 For the purpose of this section, it is important to clarify some of the terms used to
identify components of the autophagic system.6 “Primary lysosomes” refer to small vesicles
containing acid hydrolases that have not participated in a previous digestive process, whereas
“secondary lysosomes” are somewhat larger particles containing hydrolases and, in the case
of late secondary lysosomes/telolysosomes, residues of previous digestions.
“Autophagosomes” contain cytoplasmic components but no hydrolases, and finally,
“autolysosomes” or “autophagolysosomes” result from the fusion of autophagosomes with
primary or secondary lysosomes. It has been shown that with proper homogenization
techniques,142 populations of particles making up the autophagic process in cells
(autophagosomes, autolysosomes and telolysosomes) are present in tissue homogenates and
are randomly distributed.139,143 Because of their sizes (smaller than nuclei but larger than
membrane fragments (microsomes)), differential centrifugation can be used to obtain a
subcellular fraction enriched in mitochondria and organelles of the autophagic-lysosomal
system (usually the classical Mitochondrial Fraction + Light Mitochondrial Fraction [M+L
Fraction]; the L Fraction contains the highest activity for lysosomal enzymes, but the main
component is still mitochondria), which can then be subjected to discontinuous density gradient
centrifugation to separate autophagosomes, autolysosomes and lysosomes.143–145 Any part
of such a fraction can be considered to be a representative sample of tissue constituents and
used in quantitative biochemical, centrifugational and morphological studies of autophagic
particle populations. The data obtained can be further evaluated using sophisticated statistical
analysis.
The simplest studies of the autophagic process take advantage of sequestered marker enzymes,
changes in location of these enzymes, differences in particle/compartment size and differential
sensitivity of particles of different sizes to mechanical and osmotic stress (acid hydrolases are
found primarily in membrane-bound compartments and their latent activities cannot be
measured unless these membranes are lysed). For example, autolysosomes/early secondary
lysosomes are much larger than telolysosomes/late secondary lysosomes139 and the location
of enzymes in the former can be detected by an increase in the release of these enzymes by
osmotic shock or mechanical disruption.137,139,141 Such a change in enzyme accessibility
can be used to follow the time course of an exogenously induced, or naturally occurring,
autophagic process.137,139,141
Quantitative localization of enzymatic activity (or any other marker) to specific cytoplasmic
particle populations and changes in the location of such markers during autophagy can be
carried out using rate sedimentation ultracentrifugation.143 Application of a centrifugal force
to a sample of homogeneously distributed particles results in their migration at different speeds
away from the axis of rotation, carrying their markers with them. This results in a distribution
of marker activity, dependent on particle size and relative density, in fractions taken at different
distances from the axis of rotation.143 These distributions can be used to determine which
markers are in the same particles137,143 and whether or not the markers have moved to
particles with different physical properties.139 Similar results can be obtained with isopycnic
centrifugation where particles enter a density gradient (sometimes made with sucrose but iso-
osmotic media such as iodixanol, metrizamide and Nycodenz may be preferred as discussed
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below under Cautionary notes) and are centrifuged until they reach locations in the gradient
where their densities are equal to those of the gradient.143
Particle populations in subcellular fractions evaluated with quantitative biochemical and
centrifugational approaches can also be studied with quantitative morphological methods.
Detailed morphological study of the particle populations involved in the autophagic process
usually requires the use of electron microscopy. The thin sections required for such studies
pose major sampling problems in both intact cells146 and subcellular fractions.143 With the
latter, 2,000,000 sections can be obtained from each 0.1 ml of pellet volume, so any practical
sample size is an infinitesimally small subsample of the total sample.143 However, through
homogenization and resuspension, complex and heterogeneous components of subcellular
fractions become randomly distributed throughout the fraction volume. Therefore, as
mentioned above, any aliquot of that volume can be considered a random sample of the whole
volume. What is necessary is to conserve this property of subcellular fractions in the generation
of a specimen that can be examined with the electron microscope. This can be done with the
use of a pressure filtration procedure147 to deposit the contents of an aliquot of fraction volume
on a filter, which is subsequently covered with a layer of red blood cells, processed for electron
microscopy, embedded and sectioned.143 Because the direction of pressure is perpendicular
to the plane of the filter, any section containing the full pellet thickness can be considered a
random sample of the pellet volume. Because of the thinness of the sections, multiple sections
of individual particles are possible so morphometric/stereological methods146 must be used
to determine the volume occupied by a given class of particles, as well as the size distribution
and average size of the particle class. From this information the number of particles in a specific
particle class can be calculated.148 If these data are obtained for all classes of particles in the
autophagic system, the kinetics of particle interaction can be evaluated.138 Examination of
individual profiles gives information on the contents of different types of particles and their
degree of degradation, as well as their enclosing membranes.137,139 By combining the
quantitative biochemical and morphological methods described above, it is possible to show
that most of the populations of certain marker enzymes and specific cellular organelles have
similar sedimentation properties, confirming the location of these enzymes.137,148
Furthermore, these approaches permit the identification of compartments such as
autophagosomes and autolysosomes in the same subcellular fraction without cytochemistry.
139
Cautionary notes—When isolating organelles from tissues and cells in culture it is essential
to use disruption methods that do not alter the membrane of lysosomes and autophagosomes,
compartments that are particularly sensitive to some of those procedures. For example teflon/
glass motor homogenization is suitable for tissues with abundant connective tissue, such as
liver, but for circulating cells or cells in culture, disruption by nitrogen cavitation is the best
method to preserve lysosomal membrane stability.149 During the isolation procedure it is
essential to always use iso-osmotic solutions (e.g., 0.25 M sucrose) to avoid hypotonic or
hypertonic disruption of the organelles. In that respect, because lysosomes are able to take up
sucrose if it is present at high concentrations, the use of sucrose gradients for the isolation of
intact lysosome-related organelles is strongly discouraged. Other density media such as
Nycodenz, metrizamide and Percoll, cannot be transported inside lysosomes and subsequently
are more suitable for their isolation.
As with the isolation of any other intracellular organelle, it is essential to assess the purity of
each preparation, as there is often considerable variability from experiment to experiment due
to the many steps involved in the process. Correction for purity can be done through calculation
of recovery (percentage of the total activity present in the homogenate) and enrichment
(multiplying by the specific activity in the homogenate) of enzymes or protein markers for
those compartments (e.g., β-hexosaminidase is routinely used to assess lysosomal purity).
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149 Along these lines, it is essential to keep a balance sheet when using markers in biochemical
studies of autophagy. This is necessary to insure that all marker activity is accounted for and
that excessive damage to particles of interest has not occurred. Because of the time-consuming
nature of quantitative morphological studies, such studies should not be carried out until
simpler biochemical procedures have established the circumstances most likely to give
meaningful morphometric/stereological results.
Finally, it is worthwhile noting that not all lysosomes are alike. For example, as noted above,
there are differences among primary lysosomes, autolysosomes and telolysosomes.
Furthermore, what we refer to as “lysosomes” are actually a very heterogeneous pool of
organelles that simply fulfill five classical criteria, having a pH <5.6, cleaved cathepsins, the
presence of LAMP proteins, a single membrane, and the absence of endosomal and recycling
compartment markers (e.g., the mannose-6-phosphate receptor or Rab5). But even applying
those criteria we can separate lysosomes with clear differences in their proteome and other
properties, and these distinct populations of lysosomes are likely to participate in different
functions in the cell.150
11. Analyses in vivo
Monitoring autophagic flux in vivo or in organs is one of the least developed areas at present,
and ideal methods relative to the techniques possible with cell culture may not exist. One of
the most useful methods is the analysis of GFP-LC3/Atg8 (see Fluorescence microscopy
above). The morphological detection of autophagic structures (e.g., autophagosomes) by
fluorescence or electron microscopy is one approach, although there are practical limits to the
number of sections that can be prepared and analyzed. Extensive autophagy can result in
obvious changes in cell morphology and the elimination of sufficient amounts of cytoplasm to
cause cells to appear “clear.”151,152 Another useful approach is immunohistochemical
staining, an important procedure considering the role of autophagy in protecting against certain
neurodegenerative diseases, and its potential roles in myopathies, heart disease and the
response to ischemia/reperfusion, where samples may be limited to biopsies; however, this
methodology has not received extensive evaluation, and does not lend itself well to dynamic
assays. One method that has been used to monitor autophagy in myocytes is the detection of
granular ubiquitin inclusions in the cytosol;46–48 however, it is important to note that the
presence of such inclusions may actually indicate decreased autophagy or autophagic flux.
Along these lines, it is worth noting that immunodetection of LC3 is also possible using tissue
sections.153 It is likely, however, that in vivo analyses will be relatively complex. For example,
in skeletal muscle the induction of autophagy by starvation appears to occur more actively in
very young animals (e.g., in 4 to 5 week old mice) than in more elderly organisms (e.g., in four
month old mice) (Raben N, personal communication).
Some biochemical assays may be used to at least provide indirect correlative data relating to
autophagy, in particular when examining the role of autophagy in cell death. For example,
cellular viability is related to high cathepsin B activity and low cathepsin D.154 Therefore, the
appearance of the opposite levels of activities may be one indication of the initiation of
autophagy (lysosome)-dependent cell death. The question of “high” versus “low” activities
can be determined by comparison to the same tissue under control conditions, or to a different
tissue in the same organism, depending on the specific question. Finally, certain molecular
biology analyses are also possible, such as the detection of some cytokeratins that appear under
autophagic conditions.152,155
With regard to living animals, a minimally invasive method that may be used even in humans
is to measure the arteriovenous amino acid exchange rate in the peripheral tissues as a measure
of post-absorptive protein catabolism. In humans, the insulin- and amino acid-sensitive
postabsorptive (autophagic) net protein catabolism in the peripheral (mostly skeletal muscle)
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tissue can be conveniently measured by determining the amino acid exchange rate across the
lower extremities, as defined by the difference between the plasma amino acid concentrations
in the femoral artery and femoral vein multiplied by the blood flow.156–158 Amino acid
exchange studies have shown that the peripheral tissues take up amino acids during the post-
prandial (fed) state and release amino acids in the postabsorptive (fasted) state, i.e., in a state
with relatively low plasma insulin and amino acid levels. This postabsorptive release of amino
acids is strongly inhibited by infusion of insulin or by exogenous supply of amino acids
suggesting that it is mainly mediated by a lysosomal/autophagic mechanism of protein
catabolism.156–163
Finally, to obtain flux data it is necessary to include a time course parameter to follow changes
in substrate accumulation. An example of this approach is seen with the study of Drosophila
melanogaster blue cheese mutants, which accumulate ubiquitin-positive inclusions in a time-
dependent manner.164
Cautionary notes—One caution in using approaches that monitor ubiquitinated aggregates
is that the accumulation of ubiquitin may indicate a block in autophagy, inhibition of
proteasomal degradation, or may correspond to structural changes in the substrate proteins that
hinder their degradation. In addition, only cytosolic and not nuclear ubiquitin is subject to
autophagic degeneration. When analyzing cathepsin D, it is advisable to use both western blots
and activity assays; activity measurements alone can be misleading because procathepsin D is
also active. In addition, it is important to realize that the level of mature cathepsin D is usually
lower than expected in tissue that is undergoing autophagy; procathepsin D is matured in
lysosomes, and extensive vacuolization resulting from autophagy interferes with trafficking of
the enzyme through the endosome (Coto-Montes A, personal communication). Therefore,
indirect measures of autophagy may be a higher ratio of procathepsin D to cathepsin D, or an
alteration in the cathepsin B:cathepsin D activity ratio (potentially indicating the onset of
autophagic cell death).
C. Methods Warranting Special Caution
1. Acidotropic dyes
One of the most frequently used methods for following autophagy is staining with acidotropic
dyes such as monodansylcadaverine (MDC),165 acridine orange,166 LysoSensor Blue167 and
LysoTracker Red.44
Cautionary notes—Although MDC was first described as a specific marker of autophagic
vacuoles168 subsequent studies have suggested that this, and other acidotropic dyes, are not
specific markers for early autophagosomes,79 but rather label later stages in the degradation
process. For example, autophagosomes are not acidic, and MDC staining can be seen in
autophagy-defective mutants38 and in the absence of autophagy activation.169 MDC may also
show confounding levels of background labeling unless narrow bandpass filters are used. On
the other hand, in the presence of vinblastine, which blocks fusion with lysosomes, MDC
labeling increases, suggesting that under these conditions MDC can label late stage
autophagosomes.170 Along these lines, cells that overexpress a dominant negative version of
Rab7 (the T22N mutant) show colocalization of this protein with MDC; in this case fusion
with lysosomes is also blocked171 indicating that MDC does not just label lysosomes. Finally,
MDC labeling is blocked by treatment with the autophagy inhibitors wortmannin or 3-MA.
Overall, staining with MDC or its derivative monodansylpentane (MDH) is not, by itself, a
sufficient method for monitoring autophagy. Similarly, LysoTracker Red and acridine orange
are not ideal markers because they primarily detect lysosomes. For example, LysoTracker Red
has been used to provide correlative data on autophagy in Drosophila melanogaster fat body
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cells (Fig. 10).43,44 However, additional assays, such as GFP-Atg8/LC3 fluorescence or EM,
should be used to substantiate results obtained with acidotropic dyes whenever possible.
Some of the confusion regarding the interpretation of results with these dyes stems in part from
the nomenclature in this field. Indeed, the discussion of acidotropic dyes points out why it is
advisable to differentiate between the terms “autophagosome” and “autophagic vacuole,”
although they are occasionally, and incorrectly, used interchangeably. The autophagosome is
the sequestering compartment generated by the phagophore. The fusion of an autophagosome
with an endosome or a lysosome generates an amphisome or an autolysosome, respectively.
The early autophagosome is not an acidic compartment, whereas amphisomes and
autolysosomes are acidic. Archaic names for these compartments are “initial autophagic
vacuole (AVi),” “intermediate autophagic vacuole (AVi/d)” and “degradative autophagic
vacuole (AVd),” respectively. Thus, acidotropic dyes can stain late autophagic vacuoles, but
not the initial autophagic vacuole, the early autophagosome. With the above caveats in mind,
the combined use of early and late markers of autophagy is highly encouraged, and when
quantifying mammalian lysosomes, it is important to keep in mind that increases in both
lysosome size and number are frequently observed. Finally, in order to avoid confusion with
the plant and fungal vacuole, the equivalent organelle to the lysosome, we recommend the use
of the term “autophagosome” instead of “autophagic vacuole,” and the use of “autophagic
compartment” when the specific nature of the structure is not known.
2. Autophagy inhibitors and inducers
In many situations it is important to demonstrate an effect resulting from inhibition or
stimulation of autophagy (see ref. 172 for a partial listing of regulatory compounds), and a few
words of caution are worthwhile in this regard. Most chemical inhibitors of autophagy are not
entirely specific, and it is preferable to analyze specific loss-of-function Atg mutants. However,
it must be kept in mind that some apparently specific Atg gene products may have autophagy-
independent roles (e.g., Atg5 in cell death). Therefore, the experimental conditions of inhibitor
application and their side effects must be carefully considered. In addition, it must be
emphasized once again that autophagy, as a multi-step process, can be inhibited at different
stages. Sequestration inhibitors include for example, 3-MA, LY294002 and wortmannin,
which inhibit class I as well as class III phosphatidylinositol 3-kinases.132,173 The class I
enzymes generate products that inhibit autophagic sequestration, whereas the class III products
generally stimulate autophagic sequestration. The overall effect of these inhibitors is typically
to block autophagy because the class III enzymes that are required to activate autophagy act
downstream of the negative regulatory class I enzymes, although cell death may ensue in cell
types that are dependent upon high levels of protein kinase B for survival. Although ineffective
in isolated hepatocytes,174 cycloheximide is a well established inhibitor of sequestration in
vivo,131,133,134,175–181 and in certain cell types in vitro,182 and it has been utilized to
investigate the dynamic nature of the regression of various autophagic elements.132–134,
176–179 The mechanism of action of cycloheximide in short term experiments is not clear,
but it has no direct relation to the inhibition of protein synthesis.174
Most other inhibitory drugs act at post-sequestration steps. These types of agents have been
used in many experiments to both inhibit endogenous protein degradation and to increase the
number of autophagic compartments. They cause the accumulation of sequestered material in
either autophagosomes or autolysosomes, or both, because they allow autophagic sequestration
to proceed. The main categories of these types of inhibitors include the vinca alkaloids (e.g.,
vinblastine) and other microtubule poisons that inhibit fusion, inhibitors of lysosomal enzymes
(e.g., leupeptin, pepstatin A and E64d), and compounds that elevate lysosomal pH (e.g.,
inhibitors of vacuolar-type ATPases such as bafilomycin A1, and weak base amines including
ammonia, methyl- or propylamine, chloroquine, and Neutral Red, some of which slow down
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fusion). It is worth noting that lysosomal proteases fall into the three general groups (cysteine,
aspartic acid and serine). Therefore, the fact that leupeptin, a serine and cysteine protease
inhibitor, has little or no effect does not necessarily indicate that lysosomal degradation is not
taking place; a combination of leupeptin, pepstatin and E64d may be a more effective treatment.
As with the phosphatidylinositol 3-kinase inhibitors, many of these autophagy compounds are
not specific. For example, okadaic acid is a powerful inhibitor of type 1 (PP1) and type 2A
(PP2A) protein phosphatases.183 Bafilomycin A1 and other compounds that raise the
lysosomal pH may have indirect effects on any acidified compartments. Thus, although these
various agents can inhibit different steps of the autophagic pathway, their potential side effects
must be considered in interpretation of the secondary consequences of autophagy inhibition,
especially in long-term studies. For example, lysosomotropic compounds can increase the rate
of autophagosome formation by inhibiting TORC1 (Høyer-Hansen M, unpublished
observation). Along these lines, chloroquine treatment may cause an apparent increase in the
formation of autophagosomes possibly by blocking fusion with the lysosome (Dorsey FC,
Cleveland JL, personal communication). Furthermore, in addition to causing the accumulation
of autophagic compartments, many of these drugs seem to be stimulators of sequestration in
many cell types, especially in vivo.78,131,177,182,184–189 Although it is clear why these
drugs cause the accumulation of autophagic compartments, it is not known why they stimulate
sequestration. One possibility, at least for hepatocytes, is that the inhibition of protein
degradation reduces the intracellular amino acid pool, which in turn upregulates sequestration.
A time-course study of the changes in both the intra- and extracellular fractions may provide
accurate information regarding amino acid metabolism. For these various reasons, it is
important to include appropriate controls; along these lines, rapamycin or amino acid
deprivation can be utilized as positive controls for inducing autophagy. In many cell types,
however, the induction of autophagy by rapamycin is relatively slow, allowing more time for
indirect effects. Finally, it has recently been shown that a specialized class of compounds with
α, β-unsaturated ketone structure tends to induce autophagic cell death, accompanied by
changes in mitochondrial morphology.190 Due to the potential pleiotropic effects of various
drug treatments, it is incumbent upon the researcher to demonstrate that autophagy is indeed
inhibited, by using the methodologies described herein.
The use of gene deletions (e.g., in primary or immortalized Atg−/− MEFs,38 or in vivo using
transgenic knockout models191,192 including Crelox based “conditional” knockouts74,75) or
functional knockdowns (e.g., with RNAi) is the preferred approach when possible because
these methods allow a more direct assessment of the resulting phenotype. In certain contexts,
it is advisable when using a knockout or knockdown approach to examine multiple autophagy-
related genes to exclude the possibility that the phenotype observed is due to effects on a non-
autophagic function(s) of the corresponding protein, especially when examining the possibility
of autophagic cell death (in contrast, if examining whether perturbation induces clearance of
a substrate via autophagy, a single Atg gene knockout is probably sufficient). This is
particularly the case in evaluating Beclin 1, which interacts with anti-apoptotic Bcl-2 family
proteins,193 or when low levels of a target are sufficient for maintaining autophagy as is the
case with Atg5.111 Along these lines, and as stated above for the use of inhibitors, when
employing a knockout or especially a knockdown approach, it is again incumbent upon the
researcher to demonstrate that autophagy is actually inhibited, by using the methodologies
described herein. Finally, we note that the long-term secondary consequences of gene
knockouts or knockdowns are likely much more complex than the immediate effects of the
actual autophagy inhibition. To overcome this concern, tetracycline-regulated reversible
Atg5 knockout cells might be useful.111 Another strategy to specifically interfere with
autophagy is to use dominant negative inhibitors. Delivery of these agents by transient
transfection, adenovirus, or TAT-mediated protein transduction offers the possibility of their
use in cell culture or in vivo.194 However, since autophagy is an essential metabolic process
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for many cell types and tissues, loss of viability due to autophagy inhibition always has to be
a concern when analyzing cell death-unrelated questions.
There are fewer compounds that act as inducers of autophagy, but the initial characterization
of this process was due in large part to the inducing effects of glucagon, which appears to act
through indirect inhibition of mTOR via the activation of LKB1-AMPK.140,141,195
Currently, the most commonly used and specific inducer of autophagy is rapamycin, which
directly inhibits mTOR.84,196–198 TOR-independent regulation can be achieved through
lithium, sodium valproate and carbamezapine, compounds that lower the myo-inositol-1,4,5-
triphosphate levels.199 Relatively little is known about direct regulation via the Atg proteins,
but there is some indication that tamoxifen acts to induce autophagy by increasing the
expression of Beclin 1.200 Finally, new screens have identified small molecules that induce
autophagy independently of rapamycin, and allow the removal of misfolded or aggregateprone
proteins,201,202 suggesting that they may prove useful in therapeutic applications.
3. Experimental systems
Throughout these guidelines we have noted that it is not possible to state explicit rules that can
be applied to all experimental systems. For example, some techniques may not work in
particular cell types or organisms. In some cases this must be empirically determined, which
is one reason why it is important to include appropriate controls. Differences may also be seen
between in vivo or perfused organ studies and cell culture analyses. For example, insulin has
no effect on proteolysis in suspended rat hepatocytes, in contrast to the result with perfused rat
liver. The insulin effect reappears, however, when isolated hepatocytes are incubated in
stationary dishes203,204 or are allowed to settle down on the matrix (Häussinger D, personal
communication). The reason for this might be that autophagy regulation by insulin and some
amino acids requires volume sensing via integrin-matrix interactions and also intact
microtubules.205–207 Therefore, it is important to keep in mind that results from one particular
system may not be generally applicable to others.
Conclusions and future perspectives
In conclusion, we suggest a set of recommended methods for monitoring macroautophagy in
higher eukaryotes (Table 1). Importantly, investigators need to determine whether they are
evaluating autophagosome levels or autophagic flux. If the question being asked is whether a
particular condition changes autophagic flux (i.e., the rate of delivery of autophagy substrates
to lysosomes or the plant vacuole, followed by degradation), then assessment of steady state
levels of autophagosomes (e.g., by counting GFP-LC3 puncta, monitoring the amount of LC3-
II without examining turnover, or by electron microscopy) is not sufficient as an isolated
approach. In this case it is also necessary to directly measure the flux of autophagosomes and/
or autophagy cargo (e.g., in wild-type cells compared to autophagy-deficient cells, the latter
generated by treatment with an autophagy inhibitor or resulting from Atg gene knockdowns).
Collectively, we strongly recommend the use of multiple assays whenever possible, rather than
relying on the results from a single method.
As a final reminder, we stated at the beginning of this review that this set of guidelines is not
meant to be a formulaic set of rules, because the appropriate assays depend in part on the
question being asked and the system being used. Rather, these guidelines are presented
primarily to emphasize key issues that need to be addressed such as the difference between
measuring autophagy components, and flux or substrate clearance; they are not meant to
constrain imaginative approaches to monitor autophagy. Hopefully, new methods for
monitoring autophagy will continue to be developed, and new findings may alter our view of
the current assays. For example, one area that shows promise is the use of nanoparticles as
tools for monitoring autophagy,208 as they could be used in EM (e.g., providing contrast by
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using different sizes and shapes of nanoparticles) or to follow autophagic flux in living cells
(e.g., relying on the stable fluorescence of quantum dots) allowing the tracking of
autophagosomes and amphisomes. Similar to the process of autophagy, this is a dynamic field,
and we need to remain flexible in the standards we apply.
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Glossary
Amphisome  
Intermediate compartment formed by the fusion of an autophagosome with an
endosome; this compartment has not yet fused with a lysosome (also referred to
as an acidic late autophagosome)
Autolysosome/autophagolysosome 
A degradative compartment formed by the fusion of an autophagosome or
amphisome with a primary lysosome or telolysosome. Upon completion of
degradation, or when degradation has reached an end point, this compartment
(again) becomes a telolysosome (also referred to as a residual body)
Autophagosome 
A cytosolic membrane bound compartment typically denoted by a limiting
double membrane. The early autophagosome in particular contains cytoplasmic
components and organelles that are morphologically unchanged because the
compartment has not fused with a lysosome and lacks proteolytic enzymes
Autophagy  
A collection of processes typically involving degradative delivery of a portion
of the cytoplasm to lysosomes or the plant or fungal vacuole that does not involve
direct transport through the endocytic or vacuolar protein sorting, Vps, pathways
Chaperone-mediated autophagy (CMA) 
Import and degradation of soluble cytosolic proteins by chaperone-dependent,
direct translocation across the lysosomal membrane
Cytoplasm to vacuole targeting (Cvt) 
A biosynthetic pathway in fungi that transports resident hydrolases to the vacuole
through a selective autophagy-related process
Lysosome  
A degradative organelle in higher eukaryotes that compartmentalizes a range of
hydrolytic enzymes and maintains a highly acidic pH. A primary lysosome is a
relatively small compartment that has not yet participated in a degradation
process, whereas secondary lysosomes are sites of present or past digestive
activity. The secondary lysosomes include autolysosomes and telolysosomes.
Autolysosomes/early secondary lysosomes are larger compartments actively
engaged in digestion, whereas telolysosomes/late secondary lysosomes do not
have significant digestive activity and contain residues of previous digestions.
Both may contain material of either autophagic or heterophagic origin
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Macroautophagy 
The largely nonspecific autophagic sequestration of cytoplasm into a double- or
multiple-membrane-delimited compartment (an autophagosome) of
nonlysosomal/vacuolar origin and its subsequent degradation by the lysosomal
system. Note that certain proteins and organelles may be selectively degraded
via a macroautophagy-related process, and conversely, some cytosolic
components such as cytoskeletal elements are selectively excluded
Microautophagy 
Uptake and degradation of cytoplasm by protrusion, invagination or septation of
the lysosome or vacuole membrane
Mitophagy  
The selective autophagic sequestration and degradation of mitochondria
Pexophagy  
A selective type of autophagy involving the sequestration and degradation of
peroxisomes; can occur by a micro- or macroautophagic process
Phagophore  
Membrane cisterna that has been implicated in an initial event during formation
of the autophagosome. Also referred to as the “isolation membrane.”
Phagophore assembly site (PAS) 
A perivacuolar compartment or location that is involved in the formation of Cvt
vesicles and autophagosomes in yeast. The PAS may supply membranes during
the formation process or may be an organizing center where most of the
autophagic machinery resides, at least transiently
Phosphatidylinositol 3-kinase 
A family of enzymes that add a phosphate group to the 3′ hydroxyls on the inositol
ring of phosphoinositides. The class III phosphatidylinositol 3-kinases are
stimulatory for autophagy, whereas class I enzymes are inhibitory
Programmed cell death (PCD) 
Regulated self-destruction of a cell. Type I is associated with apoptosis and is
marked by cytoskeletal breakdown and condensation of cytoplasm and chromatin
followed by fragmentation. Type II is associated with autophagy and is
characterized by the presence of enhanced levels of autophagosomes. Type III is
marked by the absence of condensation, and does not involve the lysosomal
system but rather is proteasome-dependent
Vacuole  
The fungal and plant equivalent of the lysosome; this organelle also carries out
storage and osmoregulatory functions
Xenophagy  
The selective degradation of microbes (e.g., bacteria, fungi, parasites and/or
viruses) through an autophagy-related mechanism
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Figure 1.
Schematic model demonstrating the induction of autophagosome formation when turnover is
blocked versus normal autophagic flux. (A) Induction results in the initiation of autophagy
including the formation of the phagophore, the initial sequestering compartment, which
expands into an autophagosome. A defect in autophagosome turnover due, for example, to a
block in fusion with lysosomes or disruption of lysosomal functions will result in an increased
number of autophagosomes. In this scenario, autophagy has been induced, but there is no or
limited autophagic flux. This is a different outcome than the situation shown in (B) where
autophagosome formation is followed by fusion with lysosomes and degradation of the
contents, allowing complete flux, or flow, through the entire pathway.
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Figure 2.
LC3-I conversion and LC3-II turnover. (A) HEK293 and HeLa cells were cultured in nutrient-
rich medium (DMEM containing 10% FCS) or incubated for 4 h in starvation conditions
(Krebs-Ringer medium) in the absence (−) or presence (+) of E64d and pepstatin at 10 μg/ml
each (Inhibitors). Cells were then lysed and the proteins resolved by SDS-PAGE. Endogenous
LC3 was detected by immunoblotting. Positions of LC3-I and LC3-II are indicated. In the
absence of lysosomal protease inhibitors, starvation results in a modest increase (HEK293
cells) or even a decrease (HeLa cells) in the amount of LC3-II. The use of inhibitors reveals
that this apparent decrease is due to lysosome-dependent degradation. This figure was modified
from data previously published in reference 31, and is reproduced by permission of Landes
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Bioscience, copyright 2005. (B) Expression levels of LC3-I and LC3-II during starvation.
Atg5+/+ (wild-type) and Atg5−/− MEFs were cultured in DMEM without amino acids and serum
for the indicated times, and then subjected to immunoblot analysis using anti-LC3 antibody
and anti-tubulin antibody. E64d (10 μg/ml) and pepstatin A (10 μg/ml) were added to the
medium where indicated. Positions of LC3-I and LC3-II are indicated. Similar to the result in
(A), the inclusion of lysosomal protease inhibitors reveals that the apparent decrease in LC3-
II is due to lysosomal degradation as easily seen by comparing samples with and without
inhibitors at the same time points (the overall decrease seen in the presence of inhibitors may
reflect decreasing effectiveness of the inhibitors over time). Monitoring autophagy by
following steady state amounts of LC3-II without including inhibitors in the analysis can result
in an incorrect interpretation that autophagy is not taking place (due to the apparent absence
of LC3-II). Conversely, if there are high levels of LC3-II but there is no change in the presence
of inhibitors this may indicate that induction has occurred but that the final steps of autophagy
are blocked, resulting in stabilization of this protein. This figure was modified from data
previously published in reference 33, and is reproduced by permission of Landes Bioscience,
copyright 2007.
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Figure 3.
Changes in the localization of LC3 and GFP-LC3 upon the induction of autophagy. (A)
Immunofluorescence in mouse fibroblasts and human T cells. The indicated cells were left
untreated or were treated with 100 μM rapamycin for 4 h and were subjected to
immunofluorescence with a selective antibody against LC3. LC3-stained autophagic
compartments in T cells are indicated with arrows. Quantification of 20 cells similar to the
ones shown here indicated that rapamycin-treated cells had 165 ± 8 vesicles per fibroblast and
6 ± 2 vesicles per T cell. Bar, 5 μm. This figure was previously published in reference 2, and
is reproduced by permission of Landes Bioscience, copyright 2007. (B) Direct fluorescence in
stable MEF transformants. GFP-LC3-expressing Atg5+/+ and Atg5−/− MEFs were cultured in
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DMEM with 10% FBS or DMEM without amino acids and serum for 1.5 h. Cells were fixed
with 3% PFA and analyzed by fluorescence microscopy. Bar, 20 μm. This figure was
previously published in reference 69, and is reproduced by permission of Landes Bioscience,
copyright 2007.
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Figure 4.
GFP::LGG-1 is an autophagy marker in C. elegans. GFP::LGG-1 expression in the hypodermal
seam cells of (A) wild-type N2 animals and (B) daf-2(e1370) animals that have an increase in
autophagy. The arrow shows representative GFP-positive punctate areas that label pre-
autophagosomal and autophagosomal structures. This figure was modified from data
previously published in Meléndez A, Tallóczy Z, Seaman M, Eskelinen E-L, Hall DH, Levine
B. Autophagy genes are essential for dauer development and life-span extension in C.
elegans. Science 2003; 301:1387–91. Reprinted with permission from AAAS.
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Figure 5.
GFP-LC3 processing can be used to monitor delivery of autophagosomal membranes.
Atg5−/− MEFs engineered to express Atg5 under the control of the Tet-off promoter were grown
in the presence of doxycyline (10 ng/ml) for one week to suppress autophagy. Cells were then
cultured in the absence of drug for the indicated times, with or without a final 2 h starvation.
Protein lysates were analyzed by western blot using anti-LC3 and anti-GFP antibodies. The
positions of GFP-LC3-I, GFP-LC3-II and free GFP are indicated. This figure was modified
from data previously published in reference 111, FEBS Letters, 580, Hosokawa N, Hara Y,
Mizushima N, Generation of cell lines with tetracycline-regulated autophagy and a role for
autophagy in controlling cell size, pp. 2623–9, copyright 2006, with permission from Elsevier.
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Figure 6.
Regulation of the p62 protein during autophagy. (A) The level of p62 during starvation.
Atg5+/+ and Atg5−/− MEFs were cultured in DMEM without amino acids and serum for the
indicated times, and then subjected to immunoblot analysis using anti-p62 antibody (Progen
Biotechnik). This figure was previously published in reference 33, and is reproduced by
permission of Landes Bioscience, copyright 2007. (B) The level of p62 in the brain of neural-
cell specific Atg5 knockout mice. This image was generously provided by Dr. Taichi Hara
(Tokyo Medical and Dental University).
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Figure 7.
Detection of macroautophagy in tobacco BY-2 cells. (A) Induction of autophagosomes in
tobacco BY-2 cells expressing YFP-NtAtg8 (shown in green for ease of visualization) under
conditions of nitrogen limitation (Induced). Arrowheads indicate autophagosomes that can be
seen as a bright green dot. No such structure was found in cells grown in normal culture medium
(Control). Bar, 10 μm. N, nucleus; V, vacuole. (B) Ultrastructure of an autophagosome in a
tobacco BY-2 cell cultured for 24 h without a nitrogen source. Bar, 200 μm. AP,
autophagosome; P, plastid; CW, cell wall. This image was provided by Dr. Kiminori Toyooka
(RIKEN Plant Science Center).
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Figure 8.
Schematic drawing showing the formation of an autophagic body in plants and fungi. The large
size of the plant and fungal vacuole relative to autophagosomes allows the release of the single-
membrane autophagic body within the vacuole lumen. In cells that lack vacuolar hydrolase
activity, or in the presence of inhibitors that block hydrolase activity, intact autophagic bodies
accumulate within the vacuole lumen and can be detected by light microscopy. The lysosome
of most higher eukaryotes is too small to allow the release of an autophagic body.
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Figure 9.
The GFP and mRFP signals of tandem fluorescent LC3 (tfLC3, mRFP-GFP-LC3) show
different localization patterns. HeLa cells were cotransfected with plasmids expressing either
tfLC3 or LAMP-1-CFP. Twenty-four hours after the transfection, the cells were starved in
Hanks’ solution for 2 hours, fixed and analyzed by microscopy. The lower panels are a higher
magnification of the upper panels. Bar, 10 μm in the upper panels and 2 μm in the lower panels.
Arrows in the lower panels point to (or mark the location of) typical examples of colocalized
signals of mRFP and LAMP-1. Arrowheads point to (or mark the location of) typical examples
of colocalized particles of GFP and mRFP signals. This figure was previously published in
reference 116, and is reproduced by permission of Landes Bioscience, copyright 2007.
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Figure 10.
LysoTracker Red stains lysosomes and can be used to monitor autophagy in Drosophila
melanogaster. Live fat body tissues from Drosophila melanogaster were stained with
LysoTracker Red (red) and Höechst 33342 (blue) to stain the nucleus. Tissues were isolated
from fed (left) or 3 h starved (right) animals. Bar, 25 μm. This figure was modified from data
presented in reference 44, Dev Cell, 7, Scott RC, Schuldiner O, Neufeld TP, Role and regulation
of starvation-induced autophagy in the Drosophila fat body, pp. 167–78, copyright 2004, with
permission from Elsevier.
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Table 1
Recommended methods for monitoring autophagy in higher eukaryotes
Criteria Methods
Monitoring Phagophore and Autophagosome Formation by Steady State Methods
 1. Electron microscopy (increase in autophagosome quantity) Quantitative electron microscopy, immunoelectron microscopy
 2. Atg8/LC3 western blotting and ubiquitin-like protein
conjugation systems (increase in the amount of LC3-II, and Atg12
—Atg5 conjugation)
Western blot
 3. Fluorescence microscopy (increase in punctate LC3 (or
Atg18)
Fluorescence, immunofluorescence and immunoelectron microscopy
 4. TOR and Atg1 kinase activity Western blot, immunoprecipitation or kinase assays
 5. Transcriptional regulation Northern blot, or qRT-PCR
Monitoring Autophagy by Flux Measurements
 1. Autophagic protein degradation Turnover of long-lived proteins
 2. Turnover of LC3-II Western blot +/− lysosomal fusion or degradation inhibitors
 3. GFP-Atg8/LC3 lysosomal delivery, and proteolysis (to
generate free GFP)
Fluorescence microscopy, FACS
Western blot +/− lysosomal fusion or degradation inhibitors
 4. p62 western blot Western blot with qRT-PCR or northern blot to assess transcription
 5. Autophagic sequestration assays Lysosomal accumulation by biochemical or multilabel fluorescence
techniques
 6. Turnover of autophagic compartments Electron microscopy morphometry/stereology
 7. Autophagosome-lysosome colocalization and dequenching
assay
Fluorescence microscopy
 8. Sequestration and processing assays in plants Chimeric RFP fluorescence and processing, light and electron microscopy
 9. Tandem mRFP-GFP fluorescence microscopy Fluorescence microscopy of tandem mRFP-GFP-LC3
 10. Tissue fractionation Centrifugation, western blot and electron microscopy
 11. Analyses in vivo Fluorescence microscopy and immunohistochemistry
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